DEPARTMENT OF VETERANS AFFAIRS

Notice of Intent to Grant an Exclusive License

AGENCY: Department of Veterans Affairs

ACTION: Notice of Intent

SUMMARY: Notice is hereby given that the Department of Veterans Affairs (VA), Office of Research and Development, Technology Transfer Program, intends to grant to Belum Therapeutics, LLC, 505 Park Avenue, 4th Floor, New York, NY 10022, an exclusive license to U.S. Patent Nos. 8,653,028; 9,345,745; 9,585,932; 9,765,128; 10,010,583; and 10,047,132; associated with VA Invention Disclosure number 05-137 titled, “Epo-derived Peptide Agonists”.

DATES: Comments must be received on or before February 19, 2021.

ADDRESSES: Send comments to Mr. David Marks, Technology Transfer Specialist, Office of Research and Development (RD14TT), Department of Veterans Affairs, 810 Vermont Avenue, NW., Washington, DC 20420, (202) 443-5609 (this is not a toll-free number), david.marks2@va.gov.

SUPPLEMENTARY INFORMATION: The Federal Government’s patent rights in this invention are assigned to the US Government as represented by the Department of Veterans Affairs. It is in the public interest to license this invention as Belum Therapeutics, LLC has submitted a complete and sufficient application for a license. The prospective exclusive license will be royalty-bearing and will comply with the terms and conditions of 35 U.S.C. 209 and 37 CFR 404.7. The prospective exclusive license may be granted unless, within 15 days from the date of this published Notice, the Department of Veterans Affairs Office of Research and Development, Technology Transfer Program receives written evidence and argument which establishes that the grant of the license would not be consistent with the requirements of 35 U.S.C. 209 and 37 CFR 404.7.

JOHN J KAPLAN

Director, Technology Transfer Program

Office of Research and Development